This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bacterin's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Revenue for the first half of 2012 achieved 45% of our annual guidance. We have substantially increased our available inventory and marketing costs, as well as increase in our processing capabilities, which we expect to have a positive impact on revenue in third quarter of 2012 and from thereon.

Inventory increased 42% by the end of quarter from $9.4 million at the end of 2011 to $13.3 million. As of June 30, 2012, we have approximately $1.3 million of inventory at costs on consignment hospital account, which translates to approximately $7.1 million of inventory at retail value.

Inventory is now readily available through our sales force and by end of the second quarter we had 768 active facilities. We are optimizing our processing facility to meet the demand for our products, including hMatrix, which we believe will be positively impacted on our new reimbursement cost.

Largely the 72% remain solid, including the guidance range of 70% to 75%. At June 30, 2012, we had approximately $1.2 million in cash and net account receivables of approximately $6.6 million.

Before we go much further, I’d like to turn the call over to our CFO, John, who will set us the summary of the quarter and year’s financial results, when he is finish, I’ll return to give a more detail operational update and a look ahead. John?

John Gandolfo

Thanks, Guy. Now turning to our results in the second quarter of 2012, as Guy mentioned, revenue for the quarter $8.2 million, compared to $7.8 million in the previous quarter, and an increase of 9% compared to $7.5 million in the second quarter of 2011.

Second quarter 2011 sales included a stocking order sale of distributor of approximately $1.2 million and excluding this sale, quarterly revenues increased approximately 30% over the prior year.

The year-over-year increase was largely the result of increase sales generated from the company’s direct sales force and independent distributors compared to the second quarter of 2011.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,040.37 +29.69 0.16%
S&P 500 2,111.73 +4.34 0.21%
NASDAQ 5,082.9290 +12.9030 0.25%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs